PMID- 9684414
OWN - NLM
STAT- MEDLINE
DCOM- 19980807
LR  - 20191102
IS  - 0012-6543 (Print)
IS  - 0012-6543 (Linking)
VI  - 36
IP  - 4
DP  - 1998 Apr
TI  - Low molecular weight heparins for venous thromboembolism.
PG  - 25-9
AB  - Five years ago, we concluded that in patients undergoing major orthopaedic 
      surgery, prophylactic use of a low molecular weight heparin (LMWH) gave greater 
      protection against deep vein thrombosis (DVT) than did conventional 
      unfractionated heparin (UFH). The risk of bleeding appeared to be the same. It 
      was unclear whether the clinical advantages of the LMWHs offset their greater 
      cost. In the UK, four LMWHs ([symbol: see text]certoparin, dalteparin, enoxaparin 
      and tinzaparin) are now licensed for prophylaxis against venous thromboembolism 
      during or after surgery; a fifth (nadroparin) is licensed but not yet marketed in 
      the UK. Dalteparin, enoxaparin and tinzaparin are licensed for the treatment of 
      DVT. Additionally, tinzaparin is licensed for the treatment of pulmonary embolism 
      (PE). Here, we review the use of LMWHs for these indications.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Drug Ther Bull
JT  - Drug and therapeutics bulletin
JID - 0112037
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/adverse effects/*therapeutic use
MH  - Humans
MH  - Orthopedic Procedures
MH  - Postoperative Complications/*prevention & control
MH  - Thromboembolism/*prevention & control
RF  - 39
EDAT- 1998/07/31 00:00
MHDA- 1998/07/31 00:01
CRDT- 1998/07/31 00:00
PHST- 1998/07/31 00:00 [pubmed]
PHST- 1998/07/31 00:01 [medline]
PHST- 1998/07/31 00:00 [entrez]
AID - 10.1136/dtb.1998.36425 [doi]
PST - ppublish
SO  - Drug Ther Bull. 1998 Apr;36(4):25-9. doi: 10.1136/dtb.1998.36425.